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A B S T R A C T
Dual antiplatelet therapy (DAT) can decrease effectively the rate of major adverse 
cardiovascular events after drug-eluting stent (DES) implantation in high-risk coro-
nary artery disease (CAD) patients, but its implementation is associated with excess 
in bleeding events compared with aspirin monotherapy and a considerable treatment 
failure rate, namely persistence of occurrence of ischemic events, despite the use of the 
recommended dosage of the standard DAT. All large-scale antiplatelet randomized 
controlled trials have shown that the prolonged administration of DAT after coronary 
stenting provides improved thrombotic prevention at a cost of increased bleedings.
Newer antiplatelet regimens including higher maintenance doses of clopidogrel, or us-
ing the newer agents, prasugrel or ticagrelor, can effectively reduce rates of myocardial 
infarction and stent thrombosis during follow-up of high-risk CAD patients undergo-
ing an invasive therapy, but they are accompanied by an increase in bleeding rates 
and, except for ticagrelor plus aspirin, do not reduce mortality. Therefore, the chal-
lenge remains to develop therapies that more effectively inhibit platelet activation and 
have a beneficial net effect on mortality without increasing bleeding complications.
For patients receiving triple therapy, they are advised to keep the dose of aspirin as 
low as possible (75 to 81 mg); clopidogrel should be given at its standard dose of 75 
mg/day, and warfarin should be administered under tight control to achieve a slightly 
lower target INR of 2.0 to 2.5. It is also suggested that proton-pump inhibitors (PPIs) 
should be considered as prophylaxis against gastric bleeds, tending to use pantopra-
zole and esomeprazole, which have the least incriminating data regarding an inter-
action with clopidogrel. In patients with mild or moderate bleeding while on triple 
therapy, every effort should be made to maintain the INR as close to 2.0 as possible, 
and the aspirin dose should be kept at <100 mg. If bleeding persists, it is advised that 
aspirin be discontinued first, as clopidogrel seems to be more important than aspirin 
in preventing stent thrombosis after PCI.
I N T R O D U C T I O N
Stenting and dual antiplateltelet therapy (DAT) – consisting of the combination 
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of aspirin and a thienopyridine (most commonly clopidogrel) 
– represent the current practice in percutaneous coronary 
angioplasty (PCI). Stent use has effectively reduced the risk 
of restenosis and DAT eliminates the risk of stent thrombo-
sis. Indeed, DAT provides incremental platelet inhibition 
(compared with either agent alone) and more effective sup-
pression of adverse ischemic events and has been studied in 
the settings of medical therapy and PCI as well as in stroke 
prevention and treatment. However, these benefits of DAT 
are associated with an excess in bleeding events. Moreover, 
long-term duration of DAT has important implications for the 
subsequent performance of surgical procedures that require 
stopping antiplatelet therapy, which can lead to stent thrombo-
sis. Conversely, extended dual therapy prolongs the “window 
of vulnerability” for bleeding, particularly in scenarios where 
concomitant warfarin might be necessary.1-7
In addition, despite the proven clinical benefits associated 
with DAT compared with aspirin monotherapy in the treat-
ment of high-risk coronary artery disease (CAD) patients, 
recurrent ischemic events are seen in a significant percentage 
of patients during long-term follow-up.1-7 This observation 
highlights an unmet need in the treatment of the patient at 
highest risk. For example, in the TRITON trial, there was an 
1˜0% treatment failure rate (ischemic event occurrence) in 
the prasugrel arm despite the superior inhibition compared 
with clopidogrel as demonstrated in ex vivo studies of healthy 
volunteers and patients treated with the same dose.8-10
Accordingly, current DAT can decrease effectively the 
rate of major adverse cardiovascular events after drug-elut-
ing stent (DES) implantation in high-risk CAD patients, but 
its implementation is associated with two major problems 
during long-term follow-up, (a) the excess in bleeding events 
compared with aspirin monotherapy and (b) the persistence 
of a considerable treatment failure rate, namely persistence 
of occurrence of ischemic events, despite the use of the 
recommended dosage of the standard DAT.1-7 Because the 
large-scale trials of dual antiplatelet therapy did not imple-
ment simultaneous platelet function measurements, it was 
impossible to determine whether insufficient P2Y12 blockade 
marked by high on-treatment platelet reactivity to adenosine 
diphosphate (ADP) was the major cause of treatment failure 
and whether excessively low platelet reactivity was the cause 
of bleeding.1
T H E  B L E E D I N G  R I S K
Studies comparing DES and bare-metal stent (BMS) have 
shown that the timing of stent thrombosis might differ.11-17 
Stent thrombosis tends to occur earlier in BMS, whereas stent 
thrombosis in DES seems to trend later. Of particular concern 
is the observation that DES thrombosis might continue to 
occur (albeit at a very low rate) over time. In an attempt to 
prevent late thrombosis, a longer (possibly indefinite) duration 
of dual therapy is frequently recommended, specifically after 
DES in the setting of documented severe extensive atheroscle-
rotic disease.18 However, bleeding risks have become more 
problematic with the advent of widespread and prolonged 
therapy with the combination of aspirin and a thienopyridine. 
Thus, these recommendations about long-term DAT have 
important implications for the subsequent performance of 
surgical procedures that require stopping antiplatelet therapy, 
which can lead to stent thrombosis. Conversely, extended dual 
therapy prolongs the “window of vulnerability” for bleeding, 
particularly in scenarios where concomitant warfarin might 
be necessary.7,20
All large-scale antiplatelet randomized controlled trials 
(RCTs) have shown that the prolonged administration of 
DAT after coronary stenting provides improved thrombotic 
prevention at a cost of increased bleedings. In addition, despite 
the proven clinical benefits associated with DAT compared 
with aspirin monotherapy in the treatment of high-risk CAD 
patients, the rate of DAT failure continues to remain high.2-4 
Regimens, however, proposed to solve this problem can sig-
nificantly decrease ischemic events but further increase the 
incidence of major and life-threatening bleedings.8,9,19,21,22 
Indeed, most antiplatelet and antithrombotic agents that re-
duce ischemia increase bleeding, or alternatively can reduce 
bleeding at the cost of increased ischemic complications, 
thereby cancelling any net survival benefit. Thus, although 
DAT including prasugrel or higher dose of clopidogrel ef-
fectively reduces major adverse cardiac events (MACEs) and 
stent thrombosis, it enhances the rate of major bleedings and 
has no effect on the survival.8-10,19 Of particular concern is 
the observation that, considering numerous large multicenter 
RCTs in acute coronary syndromes (ACSs) published before 
PLATO, only fondaparinux in patients with NSTEMI treated 
conservatively23 and bivalirudin in patients with STEMI un-
dergoing primary PCI24 have reduced all-cause mortality. In 
both cases this result was achieved by the test agent markedly 
reducing major bleeding while effectively suppressing (but not 
reducing) rates of MI compared with control. Ticagrelor now 
has proven the bleeding-ischemia hypothesis by showing the 
converse — that an agent which decreases MI without increas-
ing overall major bleeding can also enhance survival.20
In particular, among antiplatelet strategies proposed to 
further reduce the remaining high rate of MACE during long-
term follow-up after stenting, prasugrel8,9 or high-maintenance 
dose clopidogrel19 over aspirin compared with the standard 
DAT can effectively reduce MACE and stent thrombosis but 
enhance the rate of major bleedings and have no effect on the 
survival.8,9,19 Like the above two antiplatelet strategies, ticagre-
lor compared with clopidogrel in the PLATO trial significantly 
reduced rates of MI and stent thrombosis, accompanied by 
an increase in major bleeding that was unrelated to coronary 
artery bypass graft (CABG) surgery.21-22 By contrast, however, 
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ticagrelor compared with clopidogrel significantly reduced 
all-cause mortality at 12 months in all patients (by 22% [ab-
solute difference of 1.4%], p<0.001),21 and in those patients 
undergoing an early invasive strategy (by 19% [absolute dif-
ference of 1.1%], p=0.01).22 Thus, all these three antiplatelet 
strategies, which have been proposed to further reduce the 
remaining high rate of MACE during long-term follow-up 
after stenting, can effectively reduce MACE but at a cost of 
increased bleedings. As a consequence, except for the case of 
ticagrelor plus aspirin, these bleedings seem to largely offset 
the expected life-preserving benefits from prevention of MI 
and stent thrombosis.8,9,19,21,22
Why does ticagrelor seem to reduce all-cause mortality 
whereas most other antiplatelet and antithrombotic agents that 
reduce ischemia and increase bleeding like ticagrelor have a 
neutral effect on mortality? There are some possible explana-
tions: (a) It has been shown that hemorrhagic complications 
following antiplatelet therapy have been strongly linked to 
subsequent mortality.25-29 It might be supposed that a shorter 
acting and reversible antiplatelet agent might be advantageous 
when used in patients who are in increased risk for bleeding. 
Thus, bleedings should be minor and more manageable after 
discontinuation of such antiplatelet agent, conditions that are 
apparently safer and associated with less subsequent risk. In 
TRITON, prasugrel increased CABG-related bleeding, all-
cause bleeding, and transfusions, as well as life-threatening 
and fatal bleeding which largely offset its expected benefits 
from prevention of myocardial infarction and stent thrombosis. 
As a result, total mortality at 15 months was not significantly 
different with prasugrel and clopidogrel (3.0% vs. 3.2%).8 
By contrast, in PLATO, although ticagrelor was associated 
with an increase in non-CABG-related bleeding, it tended to 
reduce major CABG-related bleeding, and did not increase 
overall major bleeding, transfusions, or life-threatening or 
fatal bleeding.21,22 Presumably this difference is explained by 
the fact that, unlike clopidogrel and prasugrel which bind ir-
reversibly to the platelet surface-membrane P2Y12 receptor, 
ticagrelor is a reversible P2Y12 blocker, with platelet function 
returning to normal 2–3 days after discontinuation (compared 
with 5–10 days after discontinuation of clopidogrel and prasug-
rel).30 As a result, while non-CABG-related bleeding might be 
increased with ticagrelor compared with clopidogrel because 
of its greater potency, such episodes might paradoxically be 
more manageable after discontinuation of ticagrelor than of 
clopidogrel. The reversibility of ticagrelor is even more crucial 
in mitigating bleeding after CABG, and facilitates the per-
formance of surgery sooner after drug discontinuation, which 
explains the trend toward less non-CABG-related bleeding 
with ticagrelor than with clopidogrel. As such, there is no 
net difference in overall major or life-threatening bleeding 
between the two agents, despite ticagrelor’s greater potency. 
According to the above, bleeding in the ticagrelor arm was 
more manageable and the “window of vulnerability” for 
bleeding very shorter after discontinuation of ticagrelor than 
of clopidogrel, a fact that led to less blood loss. It is most 
possible that the avoidance of severe hemorrhagic complica-
tions by ticagrelor has allowed the life-preserving benefits of 
reducing MI and stent thrombosis to emerge. (b) By contrast 
with most other antiplatelets, ticagrelor inhibits adenosine 
reuptake by red blood cells, an effect that might improve 
microcirculatory flow and perhaps reduce reperfusion injury 
in ACS.31 A potential favorable role for this “off-target” effect 
cannot be excluded.
According to above mentioned, in an attempt to further 
reduce the remaining high rate of MACE after stenting despite 
the standard DAT, three dual antiplatelet strategies emerged. 
Although these strategies effectively reduced the rate of MI 
and stent thrombosis, they were associated with an increased 
rate of bleeding and, except for the combination of ticagrelor 
and aspirin, did not improve the survival.8,19,22 However, aside 
from these DAT strategies in which the increased effectiveness 
was associated with increased rate of bleeding and, except for 
ticagrelor, no improvement in survival, some newer promising 
strategies including three antiplatelet agents have come up.1 
In these strategies, a third antiplatelet agent is added to the 
standard combination of clopidogrel and aspirin. Of these, 
the addition of cilostazol to conventional antiplatelet therapy 
with clopidigrel and aspirin in patients undergoing stenting is 
a promising regimen reducing both in-hospital and long-term 
adverse cardiovascular events, including mortality, without 
any increase in the incidence of major bleeding events. It is 
interesting that these results are more obvious in patients 
with high-risk profiles where the DATs including a potent 
antiplatelet agent, such as prasugrel or ticagrelor, cause more 
bleeding than in patients with low-risk profiles.1,32-36 Regard-
ing the addition of an inhibitor of the thrombin-mediated 
platelet activation to the standard DAT, the available results 
from two small phase-III preliminary RCTs suggest that this 
combination can improve clinical outcome without increasing 
bleeding complications.1,37-39
N O N - R E S P O N S I V E N E S S  T O  S T A N D A R D 
D A T  W I T H  C L O P I D O G R E L  A N D  A S P I R I N
Although the addition of clopidogrel to aspirin has re-
duced both short- and long-term incidence of ischemic car-
diovascular events related to PCI, the risk of recurrent events 
remains a major issue in a significant percentage of patients 
during long-term follow-up.2,3 Enhanced platelet reactivity, 
non-responsiveness to any of the currently used antiplatelets, 
or non-compliance to antiplatelet therapy may underlie the 
increased rate of adverse cardiovascular events after coronary 
stenting.1 In the case of confirmed non-adequate inhibition of 
platelet aggregation despite the use of recommended dosage 
of the standard DAT, certain solutions have been suggested. 
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They include (a) the use of higher doses of clopidogrel, (b) the 
replacement of clopidogrel in the standard DAT combination 
of “clopidogrel plus aspirin” with another more potent and 
improved antiplatelet agent such as prasugrel, ticagrelor, or 
elinogrel, and (c) the addition a third antiplatelet agent in 
the standard DAT such as cilostazol or a thrombin receptor 
blocker (triple antiplatelet therapy [TAT]). Among them, 
certain solutions have been investigated in RCTs and definite 
results have been concluded. Others, however, are yet under 
investigation.
Of the above regimens, prolonged combination of prasug-
rel8,9 or higher maintenance doses of clopidogrel1,19 with aspirin 
is better than the standard DAT at preventing myocardial 
infarction (MI) and stent thrombosis in patients with an ACS 
undergoing PCI. However, proportional to their potency, these 
oral regimens increase hemorrhagic complications,1,8,19 the 
occurrence of which has been strongly linked to subsequent 
mortality.1,25-29 As a result, neither of these two thienopyridines 
has been shown to improve survival in patients who underwent 
PCI for ACSs.
Ticagrelor is another oral antiplatelet agent. This is a 
non-thienopyridine P2Y12 antagonist, which like prasugrel 
is more potent and rapid-acting than clopidogrel. However, 
ticagrelor reversibly binds to the P2Y12 platelet receptors 
and inhibits adenosine reuptake by red blood cells, an ef-
fect that might improve microcirculatory flow and perhaps 
reduce reperfusion injury in ACSs.1 These two characteristics 
represent the most important advantages of ticagrelor over 
clopidogrel and prasugrel. In the PLATO trial, this agent was 
compared with clopidogrel in more than 18 500 patients with 
ACSs.21,22 Like prasugrel in TRITON trial, ticagrelor com-
pared with clopidogrel significantly reduced rates of MI and 
stent thrombosis, accompanied by an increase in major non-
CABGS-related bleeding. In contrast to prasugrel, however, 
ticagrelor compared with clopidogrel significantly reduced 
all-cause mortality at 12 months both in all patients and in 
those patients undergoing an early invasive strategy.21,22
Accordingly, these newer antiplatelet regimens includ-
ing higher maintenance doses of clopidogrel, prasugrel or 
ticagrelor over aspirin compared with standard DAT can 
effectively reduce rates of MI and stent thrombosis during 
follow-up of high-risk CAD patients undergoing an invasive 
therapy, but they are accompanied by an increase in bleeding 
rates and, except for ticagrelor plus aspirin, do not reduce 
mortality.1,8,9,19,21,22 Moreover, although each one of these 
three therapies significantly reduces the incidence of MACE 
compared with standard DAT, the treatment failure rates of 
these three newer options of DAT continue to remain high 
during long-term follow-up (e.g., treatment failure rate ~10% 
in the TRITON trial).8,9 However, the explanation for the 
high rate of DAT failure remains a critical unresolved and 
under-investigated issue. Therefore, the challenge remains 
to develop therapies that more effectively inhibit platelet ac-
tivation and have a beneficial net effect on mortality without 
increasing bleeding complications. This topic, however, will 
be discussed in the next chapter dealing with the addition of a 
third antiplatelet agent in the standard DAT such as cilostazol 
or a thrombin receptor blocker.
T R I P L E  A N T I P L A T E L E T  T H E R A P Y
Clinical manifestations of atherothrombotic disease are 
major causes of mortality and morbidity worldwide. Platelet 
activation and aggregation are ultimately responsible for the 
progression and clinical presentations of atherothrombotic 
disease. The current standard of care, dual oral antiplatelet 
therapy with aspirin and the P2Y12 ADP receptor inhibitor 
clopidogrel, has been shown to improve outcomes in patients 
with atherothrombotic disease.2-4,8,9 However, aspirin and 
P2Y12 inhibitors target the thromboxane A2 and the ADP 
P2Y12 platelet activation pathways and minimally affect 
other pathways, while agonists such as thrombin, considered 
to be the most potent platelet activator, continue to stimulate 
platelet activation and thrombosis.1 This may help explain 
why patients continue to experience recurrent ischemic events 
despite receiving such therapy. Furthermore, aspirin and 
P2Y12 receptor antagonists are associated with bleeding risk, 
as the pathways they inhibit are critical for hemostasis.2-4,8,9,19 
The challenge remains to develop therapies that more effec-
tively inhibit platelet activation without increasing bleeding 
complications. At present, two promising antiplatelet agents 
seem to meet this challenge, an inhibitor of the endogenous 
phosphodiesterase (PDE) activity and an inhibitor of the 
protease-activated receptor-1 (PAR-1) for thrombin.1
C I L O S T A Z O L
Cilostazol is a quinolone derivative that inhibits the PDE3 
enzyme in both platelet and vascular smooth muscle cells 
similar to dipyridamole, thus increasing cAMP levels. It is 
believed that this property may be important in explaining 
the enhancement of platelet inhibition when added to clopi-
dogrel and aspirin therapy. It has been shown that cilostazol 
treatment has antiproliferative effects on vascular smooth 
muscle cells and reduces the rate of hyperplasia after bal-
loon angioplasty and BMS implantation compared with 
aspirin and thienopyridines. In addition, cilostazol has an 
additive inhibitory effect on platelet p-selectin expression 
when administered with aspirin and clopidogrel therapy.1 
The addition of cilostazol to standard antiplatelet therapy 
with one or two other antiplatelets has recently proved out 
promising as regards enhancement of platelet inhibition and 
improvement of clinical outcomes without any increase in 
bleeding.32-36 According to available studies, cilostazol plus 
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aspirin is comparable to clopidogrel or ticlopidine plus aspirin 
in the prevention of 30-day major cardiac events after coronary 
stenting.1 Thus, it was proposed that cilostazol can be used as 
an alternative to thienopyridine therapy to prevent short-term 
post-stenting complications, including stent thrombosis. In 
addition to these, subsequent studies compared a triple an-
tiplatelet therapy (TAT) – consisting of cilostazol, clopidogrel 
and aspirin – with DAT including standard or higher doses of 
clopidogrel. Their results are summarized as follows: (a) TAT 
compared with DAT is associated with greater inhibition of 
ADP-induced platelet aggregation and a lower prevalence of 
low responsiveness; (b) TAT in patients with AMI undergoing 
coronary stenting results in a greater antiplatelet effect at 30 
days as compared with a high-maintenance dose clopidogrel 
or standard DAT; (c) adjunctive cilostazol to standard DAT in 
patients with high post-treatment platelet reactivity undergo-
ing coronary stenting significantly reduces the rate of this high 
reactivity and intensifies platelet inhibition as compared with a 
high-maintenance dose clopidogrel of 150 mg/day plus aspirin; 
(d) TAT significantly reduces late loss at 6 months after DES 
implantation and the occurrence of target lesion revasculariza-
tion (TLR) and major adverse cardiac events in patients with 
long coronary lesions compared with DAT; (e) TAT after DES 
implantation decreases angiographic restenosis and extent of 
late loss, resulting in a reduced risk of 9-month TLR compared 
with DAT in diabetic patients; (f) adding cilostazol at least for 
1 month to conventional DAT compared with DAT in STEMI 
patients undergoing primary PCI is associated with a signifi-
cantly lower in-hospital and 8-month cardiac death but a simi-
lar incidence of major bleeding events, and effectively reduces 
the 8-month incidence of cardiac death, total death, and total 
major adverse cardiac events, specifically in older (> 65 years 
of age), female, and diabetic patients; and (g) TAT compared 
with DAT in ACS patients undergoing stenting is associated 
with a significantly lower incidence of the long-term cardiac 
and cerebral events but similar bleeding events, specifically 
for patients with high-risk profiles. According to the above, 
the addition of cilostazol to conventional antiplatelet therapy 
with one or two other antiplatelets in patients undergoing 
stenting is a promising regimen reducing both in-hospital and 
long-term adverse cardiovascular events, including mortality, 
without any increase in the incidence of major bleeding events, 
specifically in patients with high-risk profiles. At this time, 
however, cilostazol is approved by the FDA only for treatment 
of intermittent claudication.1-32-36
I N H I B I T O R S  O F  P A R - 1
The inhibition of the PAR-1 for thrombin has been shown 
to inhibit thrombin-mediated platelet activation without 
increasing bleeding in pre-clinical models and small-scale 
clinical trials. PAR-1 inhibition in fact does not interfere with 
thrombin-dependent fibrin generation and coagulation, which 
are essential for hemostasis.1 Thus PAR-1 antagonism coupled 
with existing dual oral antiplatelet therapy may potentially of-
fer more comprehensive platelet inhibition without the liability 
of increased bleeding. Two oral thrombin receptor antagonists 
are currently in clinical trials for the treatment and prevention 
of arterial thrombosis, SCH 530348 and E-5555. Regarding 
SCH 530348, two phase-III preliminary RCTs are available. 
Their results are summarized as follows: (a) oral SCH 530348 
added to standard-of-care [aspirin, ticlopidine, and heparin] 
compared with standard-of-care in Japanese subjects with 
NSTE ACS undergoing urgent PCI significantly reduced 
the incidence of periprocedural MI [by 60%; p=0.013] and 
it was not associated with any other MACE or death and did 
not result in excess bleeding both in-hospital and during the 
60-day follow-up; 37 and (b) oral SCH 530348 administered 
concomitantly with aspirin and clopidogrel was generally 
well tolerated and did not cause increased TIMI bleeding 
compared with standard DAT in CAD patients undergoing 
non-urgent PCI.38 These results suggested that SCH 530348 is 
a potent and selective PAR-1 antagonist that does not impact 
bleeding, provided preliminary evidence for the feasibility 
and safety of thrombin receptor inhibition among patients 
with CAD undergoing PCI, and supported further clinical 
evaluation. Large phase-III clinical trials designed to assess 
the efficacy and safety of SCH 530348 in patients with high-
risk ACS receiving the full complement of antithrombotic 
treatment (TRACER) and in the setting of high-risk second-
ary prevention (TRA 2P—TIMI 50) are currently underway. 
As regards E-5555, this is another, newer thrombin receptor 
inhibitor undergoing investigation. Dose-dependent inhibi-
tion of thrombin-induced platelet aggregation by this agent 
has been demonstrated in healthy volunteers. More than 
80% inhibition of thrombin-induced platelet aggregation was 
achieved by single doses of ≥50 mg. Nearly complete inhibition 
of thrombin-induced platelet aggregation was achieved at drug 
steady state after repeated administration of 100- and 200-mg 
doses. There were no significant adverse effects or effects on 
ADP-induced platelet aggregation, coagulation, or bleeding 
time associated with E5555 administration. Two phase-II 
clinical trials assessing safety, tolerability, and the effect on 
intravascular inflammation and thrombosis in patients with 
CAD and with ACS, respectively, are being undertaken. 1,39
C O N C U R R E N T  D A T  A N D  O R A L 
A N T I C O A G U L A N T  A D M I N I S T R A T I O N
Bleeding risk in patients who need treatment with DAT 
as well as an anticoagulant such as warfarin is a growing 
problem, specifically in the context of the aging population.7 
DAT (aspirin plus a thienopyridine, usually clopidogrel) is 
given routinely in the treatment of ACS and after coronary 
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stent deployment. On the other hand, anticoagulant therapy 
might be indicated for stroke prevention in a variety of con-
ditions that include atrial fibrillation (AF) and profound left 
ventricular dysfunction as well as after mechanical prosthetic 
heart valve replacement. Triple antithrombotic therapy may be 
needed when a patient has multiple diseases, the most common 
situations being patients with AF and/or mechanical prosthetic 
heart valves who also have CAD and require a stent. This is 
a growing problem in the context of the aging population. 
Both AF and the need for prosthetic heart valves rise with 
age and so does the risk of falling, which further increases 
bleeding risk. ACS is very common, and given the increasingly 
widespread use of DES (for which DAT is recommended for 
at least one year), the significant bleeding hazards associated 
with triple antithrombotic therapy is a real issue, which will 
become worse in the future.7
Before committing a patient to triple therapy for an 
indefinite period, the physician should carefully consider 
alternative approaches. For example, in patients who require 
long-term oral anticoagulation who are undergoing stenting, 
serious consideration should be given to the use of BMS, 
for which dual antiplatelet treatment is recommended for a 
shorter time. And for AF patients, thought should be given 
to left atrial appendage occlusion devices or pulmonary vein 
ablation that could avoid the need for long-term warfarin. For 
patients needing a heart valve, the new On-X valve should be 
considered; it has lower warfarin requirements than other 
valves. New valve technology such as this will help immensely 
to reduce levels of anticoagulation needed.7,40-42
B A L A N C I N G  T H E  N E E D  F O R 
T R E A T M E N T  W I T H  T H E  B L E E D I N G  R I S K
Patients who are treated with triple therapy present signifi-
cant clinical challenges because of the imperative to balance 
bleeding risks against the risk of stopping one of the therapies. 
Unfortunately, the published information regarding use of 
triple antithrombotic therapy is very limited. Thus, concrete 
recommendations are difficult.
Data that are available suggest that up to 21% of patients 
receiving triple antithrombotic therapy need a transfusion (a 
figure that might increase with longer treatment durations), 
and the relative risk of major bleeding is three- to fivefold 
higher than in patients receiving DAT alone. But this is con-
founded by the fact that patients receiving triple therapy are 
typically older and have multiple comorbidities, which might 
increase bleeding potential. Short-term use of triple therapy 
(for one month) is associated with at least a two-fold lower 
risk of major bleeding compared with prolonged use (more 
than six months). But patients receiving DAT only after PCI 
(prolonged warfarin interruption) have a three-fold increase 
in stroke or thromboembolic events, compared with patients 
receiving triple therapy or warfarin plus a single antiplatelet 
agent.7,43,44
K E E P  A S P I R I N  D O S E  A N D 
I N T E R N A T I O N A L  N O R M A L I Z E D  R A T I O 
( I N R )  L O W
For patients receiving triple therapy, expert’s advice is 
that the dose of aspirin should be kept as low as possible (75 
to 81 mg), clopidogrel should be given at its standard dose of 
75 mg/day, and warfarin should be administered under tight 
control to achieve a slightly lower target INR of 2.0 to 2.5. 
They also suggest that proton-pump inhibitors (PPIs) should 
be considered as prophylaxis against gastric bleeds.7,43,44
The issue of using PPIs with clopidogrel has been fraught 
with controversy as it is thought that there may be an interac-
tion between these agents. The latest consensus of experts 
is that there is no good evidence that events are increased 
when PPIs are given with clopidogrel. The studies suggest-
ing increased events are confounded. Many physicians do 
give PPIs as prophylaxis to patients on triple antithrombotic 
therapy, but they tend to use pantoprazole and esomeprazole, 
which have the least incriminating data regarding an interac-
tion with clopidogrel.43,44
P C I  I N  P A T I E N T S  T A K I N G  W A R F A R I N
In patients on warfarin who need PCI, it is suggested that 
it may be better to choose a BMS and commit the patient 
to a short course of clopidogrel, rather than to an extended 
course of triple therapy. It is recommended that BMS should 
be considered for use in target vessels less likely to benefit 
from DES (for example, vessels >3 mm in diameter, short le-
sions <15 mm, and de novo stenoses). Clopidogrel regimens 
as short as two to four weeks have been reported to offer 
adequate protection from early stent thrombosis with BMS, 
but current guidelines recommend approximately three to six 
months of triple therapy, after which patients may continue on 
aspirin and warfarin alone. DES use and acceptance therefore 
the increased risk of bleeding should be reserved for very 
high-risk lesions. For patients with high bleeding risk treated 
with a DES, it is advised that triple therapy may be limited 
to three to six months, with warfarin plus clopidogrel and a 
prophylactic PPI continued thereafter.7,26,43,44
 
H O W  T O  C O P E  W I T H  B L E E D I N G
Bleeding on triple therapy is a particularly difficult prob-
lem. Severe or life-threatening bleeding usually requires re-
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versal of warfarin therapy and, in some cases, platelet transfu-
sions to counteract clopidogrel therapy. If DAT requires urgent 
discontinuation, the patient should be closely monitored for 
the risk of stent thrombosis. In patients with mild or moderate 
bleeding, every effort should be made to maintain the INR as 
close to 2.0 as possible, and the aspirin dose should be kept 
at <100 mg. If bleeding persists, it is advised that aspirin be 
discontinued first, as clopidogrel seems to be more important 
than aspirin in preventing stent thrombosis after PCI.7,26,43,44
N E W  D R U G S  A N D  S T E N T  D E S I G N S
All these uncertainties will be further compounded by 
the imminent arrival on the market of new anticoagulant and 
antiplatelet drugs and new stent designs.
The factor Xa antagonists, rivaroxaban (Xarelto) and 
apixaban, as well as direct thrombin inhibitors, such as da-
bigatran (Pradaxa), which might replace warfarin, also dra-
matically increase bleeding risk when combined with aspirin 
plus clopidogrel and so may not much help patients requiring 
triple therapy.
The new antiplatelet drug prasugrel is more potent than 
clopidogrel and associated with higher bleeding rates and so 
is not likely to be suitable for use in combination with war-
farin. However, the newer compound AZD 6140 (ticagrelor 
[Brilinta]) is shorter acting and reversible, which might be 
advantageous when used in patients who also require warfa-
rin. The new under-investigation protease-activated receptor 
1 (PAR-1) antagonist SCH 530348 has shown promising 
results in preliminary trials, with no increase in bleeding yet 
seen. If this drug becomes clinically available, it may replace 
clopidogrel in patients who require warfarin, giving a modified 
triple combination that might have an improved safety profile. 
Finally, the cyclooxygenase inhibitor triflusal is potentially as-
sociated with lower bleeding risk and has been demonstrated 
as safe and effective in combination with warfarin in patients 
with atrial fibrillation and so could prove useful in patients 
requiring oral anticoagulation and undergoing PCI, but ran-
domized studies are needed.21,22,32-39
In addition, new stents are being introduced with thinner 
struts and polymer coatings, which are thought to be associ-
ated with better endothelialization and less vascular inflam-
mation than previous DESs. And another new generation of 
stents that employ bioabsorbable polymers or are designed 
to capture circulating endothelial precursor cells to promote 
vascular healing is in development, and the hope is that these 
stents could be less subject to late thrombosis and might re-
quire shorter durations of dual antiplatelet therapy.7,43,44
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